Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Block Listing Six Monthly Return

28th Apr 2025 17:52

RNS Number : 5059G
Avacta Group PLC
28 April 2025
 

 

 

 

 

 

Avacta Group plc

 

("Avacta" or "the Group" or "the Company")

 

Block Listing Six Monthly Return

 

LONDON AND PHILADELPHIA - April 28, 2025, Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

 

Name of applicant:

Avacta Group plc

Name of scheme:

EMI scheme

Period of return:

From:

28 October 2024

27 April 2025

Balance of unallotted securities under scheme(s) from previous return:

275,380

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

47,000

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

228,380

 

Name of applicant:

Avacta Group plc

Name of scheme:

LTIP/ESOS scheme

Period of return:

From:

28 October 2024

27 April 2025

Balance of unallotted securities under scheme(s):

5,913,257

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

4,366,882

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1,546,375

 Name of contact:

Brian Hahn, Company Secretary

Telephone number of contact:

+ 44 (0) 1904 217070

 

Ends-

 

For further information from Avacta Group plc, please contact:

 

Avacta Group plc

Michael Vinegrad, Group Communications

Director

https://avacta.com/

Peel Hunt (Nomad and Joint Broker)

James Steel / Chris Golden

 

 

 

www.peelhunt.com

 

Panmure Liberum (Joint Broker)

Emma Earl / Will Goode / Mark Rogers

 

ICR Healthcare

Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert

 

www.panmureliberum.com

 

[email protected]

 

 

Investor Contact

Renee Leck

THRUST Strategic Communications

 

 

 

[email protected]

 

Media Contact

Carly Scaduto

Carly Scaduto Consulting

 

[email protected] 

 

 

About Avacta https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRPPUGACUPAGQR

Related Shares:

Avacta Group
FTSE 100 Latest
Value8,544.13
Change-53.29